October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 X...
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx' drug s...
argenx SE - Special Call Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Roeland Vanhauwaert Peter Ulrichts - Chief Scientific Officer Luc Truyen - Chief Medical Officer Rebecca Shilling Jeff Guptill Tim Van Hauwermeiren - Co-Founder, CEO & Executive Director Conference Call Participants Steven Burden Ricardo Maselli Danielle Brill Bonge...
argenx's blockbuster Vyvgart drives rapid growth, but heavy reliance on one product and US sales creates concentration risk. The company's robust R&D investment and Immunology Innovation Program fuel a strong pipeline, with empasiprubart showing promising diversification potential. Risks include intense competition, potential loss of exclusivity, and US pricing policy changes, but argenx's larg...
argenx SE (NASDAQ:ARGX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Karl Gubitz - Chief Financial Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning. Welcome to Morgan Stanley's Global Healthcare Conference.
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and never achieve them.
August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.